Lifeboat Foundation

As the new year begins, we approach one of the most awaited life extension events of 2019: the Undoing Aging conference.

Starting off with a success

The Undoing Aging conference series started off in 2018, with the first being held in Berlin, Germany, in mid-March. Especially when you consider that UA2018 was the inaugural event of the series, it was extremely successful; the three-day conference organized by SENS Research Foundation (SRF) and Forever Healthy Foundation (FHF) brought together many of the most illustrious experts in the fields of aging research, biotechnology, regenerative medicine, AI for drug discovery, advocacy and policy, and business and investment.

Continue reading “Anticipation Is Growing for Undoing Aging 2019” »

China is the future of global conservation, according to Sir Tim Smit, the maverick businessman and environmentalist who created the Eden Project.

• A group of hospitals have built a nonprofit generic drugmaker called Civica Rx.
• On Monday, another 12 health systems joined the organization.
• The hope is to make generic drugs that are in shortage or have artificially high prices based on what hospitals need.

Hospitals have a creative plan to tackle the high price and frequent shortages of generic drugs.

The nonprofit company, dubbed Civica Rx, was first announced in early 2018, and has gained a lot of attention from other hospitals around the US who are interested in being a part of the venture.

ARMONK, N.Y., Jan. 4, 2019 /PRNewswire/ — IBM (NYSE: IBM) Chairman, President and CEO Ginni Rometty will deliver the opening keynote at CES 2019 on Tuesday, Jan. 8. CES is the largest and one of the most influential technology events in the world.

Rometty will show how technologies like artificial intelligence, blockchain and cloud are reshaping the world of business, and, in turn, our daily lives. She also will talk about what’s coming next in these pioneering technologies – and how new data will revolutionize how we live, work and play. Rometty shares perspective on the future of technology in the Consumer Technology Association magazine It Is Innovation (i3) CES edition: https://www.nxtbook.com/nxtbooks/manifest/i3_20190102

Rometty will be joined onstage by Ed Bastian, CEO of Delta Air Lines; Charles Redfield, executive vice president of Food for Walmart; and Vijay Swarup, vice president of R&D for ExxonMobil.

Continue reading “IBM CEO Ginni Rometty Delivers Opening Keynote at CES 2019 on What’s Next in Artificial Intelligence, Blockchain and Quantum Computing” »

By the time he was diagnosed with metastatic melanoma, Luke Simons, now 83, had already watched his wife and his longtime business partner struggle with cancer. His wife had chemo for her breast cancer 20 years ago. His business partner with multiple myeloma died 5 years ago. “I was obviously aware of what it could do,” he says of cancer. And of chemo, “my God, that can be just horrible what that can do to you.”

As soon as he got the diagnosis, Simons’ doctor at Vanderbilt-Ingram Cancer Center (where his wife is on the board) told him about how president Jimmy Carter’s metastatic melanoma had just become undetectable after taking Merck’s new drug Keytruda, which enables a person’s immune system to recognize and attack cancer cells. The doctor gave Simons the option of Keytruda, and he took it.

After his first dose, Simons developed pneumonitis, which he aptly describes as a “fever in my lungs,” that made his doctor question whether to continue the treatment. He did, and the cancer that had spread to Simons’ brain and pancreas is not showing up on scans, three years later.

Continue reading “Can Cancer Care Be Industrialized? Vanderbilt And GE Are Teaming Up To Find Out” »

Analysts say there are just four companies with sufficient resources and know-how to produce hypersonic weapons: Northrop Grumman, Boeing, Lockheed Martin and Raytheon.

Defense Department officials say they want to start fielding advanced hypersonic weapons systems “in the thousands.” Defense contractors see a business opportunity.

The 3 key ingredients for attracting investors to your crowdfunding (ICO/STO) campaign

Below is a redacted and slightly edited and updated version of a memo provided to a client regarding how to attract investors to their business, in mid 2017. For background, they’re a 5 year old private investment firm, whose stock is traded OTC and who invest in startups focused on blockchain tech. To further this model they were exploring additional ways to raise capital, specifically to acquire more startups. Below is a high level framework of what investor “whales” are looking for. This is not investment advice. These are redacted insights into what you should be considering if you’re looking to also engage potential investors in your business enterprise.

If you don’t have time to read it all, I’ll summarize: It still takes money to make money.

Note — all crowdfunding campaigns (regardless of if you call them ICOs / STOs) require a legitimate business model, tangible solutions to real problems, market size worth investing in and the potential for 100x returns. Otherwise, whales aren’t interested in 10x returns.

Continue reading “Magic Whale Formula” »

Thanks to Authority Magazine and Fotis Georgiadis for the interview — Bioquark inc. (http://www.bioquark.com) — Regeneration, Disease Reversion, Age Rejuvenation — https://medium.com/authority-magazine/the-future-is-now-we-a…cc6dc8ebf1

New program coming on-line at Bioquark Inc. (www.bioquark.com) — Ectocrine interactions (the“Ectocrinome”) represents a completely unexplored area related to human health

https://www.prweb.com/releases/bioquark_inc_and_ectocrine_te…004155.htm